Peter Seeberger

Peter Seeberger has extensive work experience in various prestigious organizations. Peter has been serving as the Director at the Max Planck Institute of Colloids and Interfaces since 2009. Additionally, they are a Professor at the Freie Universität Berlin since February 2009. Peter Seeberger is also a Co-Founder and Board Member of Tacalyx GmbH since June 2018 and GlycoUniverse GmbH & Co. KGaA since January 2013. From July 2015 to May 2020, they served as a Co-Founder and Member of the Board at Vaxxilon AG.

Furthermore, Peter Seeberger has held significant roles outside academia. Peter was the Vice President at Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation since July 2021. Peter has also served as an Affiliate Professor at The Sandford-Burnham Institute for Medical Research from May 2003 to April 2014, and as a Co-Founder and Member of the Board at Ancora Pharmaceuticals from May 2002 to October 2013. Additionally, they co-founded i2Chem in 2007 and held the role of Co-Founder until February 2012.

Overall, Peter Seeberger's work experience spans across diverse organizations, highlighting their expertise in academia, research, and entrepreneurship.

Peter Seeberger completed their PhD in Biochemistry from the University of Colorado Boulder, from 1990 to 1995. Prior to that, they attended FAU Erlangen-Nürnberg from 1987 to 1990 for their Chemie/Diplom degree. Additionally, Peter Seeberger has some unspecified education experience at the University of Colorado.